Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial [2] (multiple letters)

Cancer

Volumn 104, Issue 9, 2005, Pages 2033-2034

  Altundag, Ozden ^a   Altundag, Kadri ^b   Boruban, Cem ^c   Silay, Yavuz S ^d   Turen, Selahattin ^e   Krug, Lee M ^f  

^a Hacettepe University Institute of Oncology ^*

^b HACETTEPE UNIVERSITY   (Turkey)

^c Selcuk University Faculty of Medicine   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IMATINIB; STEM CELL FACTOR RECEPTOR;

AUTOCRINE EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GROWTH STIMULATION; HISTOPATHOLOGY; HUMAN; LETTER; LUNG SMALL CELL CANCER; PARACRINE SIGNALING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 27244449809     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21407     Document Type: Letter

References (0)